Buldukoglu Osman Cagin, Erzin Yusuf, Cekin Ayhan Hilmi, Danese Silvio
Department of Gastroenterology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Türkiye.
Department of Gastroenterology, İstanbul Cerrahpaşa University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.
Turk J Gastroenterol. 2025 Jun 2;36(6):336-342. doi: 10.5152/tjg.2025.25148.
Ulcerative colitis (UC) is a chronic, inflammatory disease of the colon. The unpredictable, systemic, and debilitating nature of UC puts disease management and patient monitoring at a pivotal point. Despite substantial development in pharmacotherapies for UC in recent years, a significant proportion of patients either fail to respond to treatment or lose their response over the course of the disease. The backbone of disease management in UC is 5-aminosalicylic acid (5-ASA), but patients unresponsive to 5-ASA or with severe disease require advanced therapies including tumor necrosis factor-alpha inhibitors (TNFi), anti-integrins, anti-interleukins and small molecule therapy, Janus kinase (JAK) inhibitors, and S1PR modulators. This review will briefly overview the current state of medical therapeutic options in UC, with further detailing the molecular and clinical aspects of Etrasimod, a sphingosine-1-phosphate receptor (S1PR) modulator.
溃疡性结肠炎（UC）是一种结肠的慢性炎症性疾病。UC不可预测、全身性且使人衰弱的特性使疾病管理和患者监测处于关键阶段。尽管近年来UC的药物治疗有了很大进展，但仍有相当一部分患者要么对治疗无反应，要么在病程中失去反应。UC疾病管理的主要药物是5-氨基水杨酸（5-ASA），但对5-ASA无反应或患有严重疾病的患者需要先进的治疗方法，包括肿瘤坏死因子-α抑制剂（TNFi）、抗整合素、抗白细胞介素和小分子疗法、Janus激酶（JAK）抑制剂以及鞘氨醇-1-磷酸受体（S1PR）调节剂。本综述将简要概述UC药物治疗选择的现状，并进一步详细介绍S1PR调节剂艾曲莫德的分子和临床方面。
